Clinical Study on Treating Liver Metastases from Digestive Tract Cancer with Shenghe Powder Combined with Interventional Therapy

Objective: To explore the therapeutic ef fects of transcatheter hepatic arterial chemoembolization (TACE) plus Shenghe po wder for patients with liver metastases from digestive tract cancer. Methods: 54 patients with unresectable liver metastases from digestiv e tract cancer were randomized to two groups. Treated group of 28 cases were tre ated with TACE plus Shenghe powder, controled group of 26 cases were treated wit h TACE alone. Results: The short-term effective rate (CR+ PR) was 46.43% in treated group and 30.77% in controled group (P0.05). The 0.5-, 1-, 2-, 3-year survival rate in treated group was 92.86%, 71.43%, 46. 43% and 28.57% respectively, significantly higher than that of 84.62%, 61.54%, 2 6.92% and 11.54% in controled group (P0.05). The mean survival period in t wo groups was 23.4 months and 16.4 months respectively, the differences were sta tistically significant (P0.05). Meanwhile the treated group could effectiv ely ameliorate the clinical symptoms, improve hepatic functions, lower AFP. No o bvious side effect was found. Conclusion: Shenghe powder p lus TACE could improve the survival quality and prolonging the survival time to patients with metastastic cancer of the liver.